1. Generics Bulletin
  2. >>Archive

Pfizer to divide firm into three businesses

 
• By Grace Montgomery

Pfizer has unveiled plans to restructure the company into three business units, separating biosimilars, generics and OTC medicines. Biosimilars will be housed in the US firm’s ‘Innovative Medicines’ division, alongside a new hospital business unit for anti-infectives and sterile injectables; an ‘Established Medicines’ segment will incorporate “certain generics” with Pfizer’s off-patent solid oral-dose legacy brands, “operating with substantial autonomy within Pfizer”; and a ‘Consumer Healthcare’ division will include the company’s OTC medicines. The changes will come into effect at the start of 2019.

Pfizer has unveiled plans to restructure the company into three business units, separating biosimilars, generics and OTC medicines. Biosimilars will be housed in the US firm’s ‘Innovative Medicines’ division, alongside a new hospital business unit for anti-infectives and sterile injectables; an ‘Established Medicines’ segment will incorporate “certain generics” with Pfizer’s off-patent solid oral-dose legacy brands, “operating with substantial autonomy within Pfizer”; and a ‘Consumer Healthcare’ division will include the company’s OTC medicines. The changes will come into effect at the start of 2019.

“This new structure represents a natural evolution of these businesses, given the ongoing strength of our in-market products and our late-stage pipeline,” commented Ian Read, Pfizer’s chairman and chief executive

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.